Dr. Choudhury on Targeted Therapy in Prostate Cancer

Video

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses the use of targeted therapy in prostate cancer.

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses the use of targeted therapy in prostate cancer.

The most prominent targeted therapies are those that target the androgen receptor (AR), says Choudhury. However, there are several promising approaches that target signaling pathways other than the AR pathway, including AKT inhibitors. For example, patients who have lost PTEN seem to be more responsive to downstream inhibition of AKT.

Then, there are PARP inhibitors, which seem to benefit patients with BRCA1/2 mutations. There may also be overlap between ATM and DNA damage response, although this has yet to be fully elucidated, says Choudhury. The initial publication demonstrating a benefit with olaparib (Lynparza) in the metastatic setting seemed to include patients with ATM loss. However, in the TRITON study, patients with ATM mutations did not seem to have a response to PARP inhibitors. Now the theory is that PARP inhibitors are only beneficial in patients with BRCA1/2 alterations.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,